Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-09-18
2010-06-08
Wollenberger, Louis (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07732592
ABSTRACT:
The present invention provides for a transgenic animal model that constitutively expresses a protein encoded by the NPM-ALK gene in lymphoid tissue, and exhibits enhanced and accelerated development of a T cell lymphoproliferative disorder or B cell plasma cell tumor, together with the identification of cells transduced with the ALK tyrosine kinase gene or fusion proteins thereof, and methods for using this animal model and cells for screening compounds or treatments for antitumor activity. In preferred embodiments, the animal is a transgenic mouse that expresses a human NPM-ALK gene operably linked to human regulatory sequences, and the cells of the mouse have at least one copy of the NPM-ALK transgene, whereby the mouse constitutively expresses a protein encoded by the NPM-ALK transgene. The animals and cells of the invention are useful in the study of NPM-ALK-dependent lymphomagenesis and plasma cell tumors and in the development of treatments for these conditions.
REFERENCES:
patent: 2001/0021505 (2001-09-01), Morris et al.
Piva et al. (2006) “Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas” Blood 107(2):689-697 showed inhibition of tumor cell growth in vitro and in vivo in a mouse using an shRNA comprising instant SEQ ID No. 5.
Sausville et al. (2001) “Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms” J Clin Oncol 19:2319-2333.
Brummelkamp et al. (2002) Science 296:550-552. cited by examiner.
Ritter et al. (2003) Oligonucleotides 13:365-373. cited by examiner.
Vickers et al. (2003) J. Biol. Chem. 278:7108-7118. cited by examiner.
Agrawal et al. Antisense therapeutics: is it as simple as complementary base recognition? 2000 Mol. Med. Today: Reviews. vol. 61, pp. 72-81.
Opalinska et al. Nucleic acid therapeutics: basic principlese and recent applications. 2002 Nature Reviews: Drug Discovery vol. 1, pp. 503-514.
Caplen RNAi as a gene therapy approach. Expt Opin. Biol. Ther. 2003, vol. 3, pp. 575-586.
Zhang, et al. Current Pharmaceutical Biotechnolongy 2004, vol. 5, p. 1-7.
Check, Nature, 2003, vol. 425, p. 10-12.
Elbashir et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. 2001 Nature vol. 411:pp. 494-498.
Paddison et al. Stable suppression of gene expression by RNAi in mammalian cells 2002 Proc. Natl. Acad. Sci. vol. 99(3):pp. 1443-1448.
Johnston et al. Targeted inhibition of NPM-ALK gene expression with resultant decreased cell viability by tumor specific small interfering RNAs in anaplastic large cell lymphoma Nov. 2003 Blood vol. 102(11): 25A (Meeting Abstract #76).
Clare R. Ozawa, et al. Annl Rev of Pharm & Toxic., 40, 295-315 (2000).
U. Ritter, et al., Olligonucleotides, 13, 365-373 (2003).
Francesco Turturro, et al., Clinical Cancer Research, 8, 240-245 (2002).
Roberto Chiarle, et al., Blood, 101, 1919-1927 (2003).
Lorena Passoni, et al., Leukemia & Lymphoma, 44, 1675-1681 (2003).
Chiarie Roberto
Inghirami Giorgio
Klauber & Jackson LLC
New York University
Wollenberger Louis
LandOfFree
ALK protein tyrosine kinase, cells and methods embodying and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ALK protein tyrosine kinase, cells and methods embodying and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ALK protein tyrosine kinase, cells and methods embodying and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4180476